PLASMA-FIBRINOGEN LEVELS AND FIBRINOGEN GENOTYPE IN NON-INSULIN-DEPENDENT DIABETICS

被引:0
作者
SNOWDEN, C
HOULSTON, R
LAKER, MF
KESTEVEN, P
ALBERTI, KGMM
HUMPHRIES, SE
机构
[1] RAYNE INST, DEPT MED, NEWCASTLE UPON TYNE WC1E 6JJ, ENGLAND
[2] UNIV NEWCASTLE UPON TYNE, DEPT CLIN BIOCHEM, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND
[3] FREEMAN RD HOSP, DEPT HAEMATOL, NEWCASTLE UPON TYNE NE7 7DN, TYNE & WEAR, ENGLAND
关键词
NIDDM; FIBRINOGEN; RFLP; MACROVASCULAR DISEASE;
D O I
暂无
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The association between plasma fibrinogen levels, fibrinogen genotype, and the development of macrovascular disease was studied in 100 patients with non-insulin dependent diabetes mellitus (NIDDM). The mean plasma fibrinogen levels in patients with macrovascular disease was higher than those without, although the difference was not statistically significant (3-67 g 1-1, and 3.43 g l-1, respectively). The frequency of the rare allele of the fibrinogen gene DNA polymorphism detected with the restriction enzyme Bc1I was slightly higher in the group of patients with disease, but the difference was not statistically significant (0.20 vs 0. 16). The frequency of the TaqI polymorphism rare allele was the same in both groups (0.30 vs 0.31). However, the Bc1I polymorphism was strongly associated with plasma fibrinogen levels, with those patients heterozygous for the rare allele having mean levels 16 per cent higher than those lacking the allele (3.81 g l-1 vs 3.28 g l-1, p<0.05). This data demonstrates that variation at the fibrinogen locus is involved in determining fibrinogen levels in patients with NIDDM, and suggests the possibility that fibrinogen genotype and plasma fibrinogen levels could be one of the factors making a small contribution to the development of macrovascular disease in diabetic patients.
引用
收藏
页码:159 / 168
页数:10
相关论文
共 28 条
  • [1] BERG K, 1989, CLIN GENET, V36, P229
  • [2] ANALYSIS OF PLASMA-LIPIDS AND APOLIPOPROTEINS IN INSULIN-DEPENDENT AND NONINSULIN-DEPENDENT DIABETICS
    BRIONES, ER
    MAO, SJT
    PALUMBO, PJ
    OFALLON, WM
    CHENOWETH, W
    KOTTKE, BA
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1984, 33 (01): : 42 - 49
  • [3] CONNOR JM, 1992, J MED GENET, V29, P480
  • [4] INTERACTION OF A LIVER-SPECIFIC NUCLEAR FACTOR WITH THE FIBRINOGEN AND ALPHA-1-ANTITRYPSIN PROMOTERS
    COURTOIS, G
    MORGAN, JG
    CAMPBELL, LA
    FOUREL, G
    CRABTREE, GR
    [J]. SCIENCE, 1987, 238 (4827) : 688 - 692
  • [5] DURRINGTON PN, 1986, BRIT HEART J, V56, P206, DOI 10.1136/hrt.56.3.206
  • [6] FIBRINOGEN GENOTYPE AND RISK OF PERIPHERAL ATHEROSCLEROSIS
    FOWKES, FGR
    CONNOR, JM
    SMITH, FB
    WOOD, J
    DONNAN, PT
    LOWE, GDO
    [J]. LANCET, 1992, 339 (8795) : 693 - 696
  • [7] STUDIES OF COMPOSITION AND STRUCTURE OF SERUM LIPOPROTEINS - ISOLATION PURIFICATION AND CHARACTERIZATION OF VERY LOW DENSITY LIPOPROTEINS OF A HUMAN SERUM
    GUSTAFSON, A
    ALAUPOVIC, P
    FURMAN, RH
    [J]. BIOCHEMISTRY, 1965, 4 (03) : 596 - +
  • [8] HAMSTEN A, 1987, LANCET, V2, P988
  • [9] ROLE OF GENETIC-VARIATION AT THE FIBRINOGEN LOCUS IN DETERMINATION OF PLASMA-FIBRINOGEN CONCENTRATIONS
    HUMPHRIES, SE
    COOK, M
    DUBOWITZ, M
    STIRLING, Y
    MEADE, TW
    [J]. LANCET, 1987, 1 (8548) : 1452 - 1455
  • [10] FIBRINOGEN AND RISK OF CARDIOVASCULAR-DISEASE - THE FRAMINGHAM-STUDY
    KANNEL, WB
    WOLF, PA
    CASTELLI, WP
    DAGOSTINO, RB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 258 (09): : 1183 - 1186